Drug intelligence / Profile preview

212Pb-TCMC-YS5

Development stage: Preclinical
Lead developer: Fortis Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

212Pb-TCMC-YS5 is a novel CD46-targeted alpha-particle radioimmunotherapy developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It consists of the human monoclonal antibody YS5, which binds to a tumor-selective epitope of CD46, conjugated via the TCMC chelator to Lead-212 (212Pb). 212Pb acts as an in vivo generator for the high linear energy transfer (LET) alpha-emitting daughter isotopes 212Bi and 212Po. This targeted radiotherapy delivers potent alpha radiation directly to malignant cells, inducing lethal double-strand DNA breaks regardless of oxygen levels or resistance to conventional chemotherapy. Preclinical studies have demonstrated significant tumor growth inhibition and improved survival in models of both adenocarcinoma and small cell neuroendocrine prostate cancer subtypes.

Other names: CD46-targeted alpha therapyCD-46-targeted alpha therapyCD 46-targeted alpha therapy212Pb-radiolabeled human antibody YS5

Targets

CD46 (CD46 Molecule)

Beyond the preview

Go deeper on 212Pb-TCMC-YS5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 212Pb-TCMC-YS5.

Explore the full profile